Fi­nal AC­TIV-2 en­roll­ment is stopped, leav­ing tiny biotech with­out a sec­ond PhI­II study

The NIH’s AC­TIV-2 tri­al has proved a high­ly suc­cess­ful ef­fort, ex­am­in­ing sev­er­al dif­fer­ent Covid-19 treat­ments in an out­pa­tient set­ting and re­sult­ing in a few EUAs for Eli Lil­ly and As­traZeneca. But now it ap­pears to have served its pur­pose.

Synair­gen, the last phar­ma com­pa­ny par­tic­i­pat­ing in the tri­al in which the NIH was still en­rolling pa­tients, re­vealed Thurs­day morn­ing the agency is halt­ing all pa­tient re­cruit­ment in the plat­form study. NIH re­searchers made the de­ci­sion due to the “shift­ing na­ture of the pan­dem­ic” mak­ing Covid-19 tri­als much more dif­fi­cult to run, a like­ly ref­er­ence to Omi­cron sub­sid­ing in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER